dimanche 15 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· February 6, 2026

Amazon Q4 Earnings Miss Estimates, Shares Slide on $200B Capex Plan

View original at finance.yahoo.com
“Net sales of $213.4 billion rose 14% year over year, which was ahead of management's guidance of $206-$213 billion”
Verbatim excerpt from the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Graviton5 is up to 40% more price-performant than leading x86 processors

    80% confidence
  • Amazon LEO commercial rollout is expected later in 2026

    80% confidence
  • Net sales guidance for Q1 2026 is between $173.5 billion and $178.5 billion, representing 11% to 15% growth

    80% confidence
  • Graviton is used by more than 90% of the top 1,000 AWS customers

    80% confidence
  • Operating income guidance for Q1 2026 is expected to range between $16.5 billion and $21.5 billion

    80% confidence
  • Shoppers using Rufus show 60% higher purchase completion rates

    80% confidence
  • Plans more than 20 Amazon LEO satellite launches in 2026 and over 30 in 2027

    80% confidence
  • AWS custom chips business including Trainium and Graviton now has a combined annual revenue run rate of more than $10 billion and is growing at triple-digit percentages year over year

    80% confidence
  • Amazon Bedrock is now a multibillion-dollar annualized run rate business with customer spend growing 60% quarter over quarter

    80% confidence
  • Trainium4 is expected to start delivering in 2027

    80% confidence
  • Plans to invest approximately $200 billion in capital expenditures in 2026, predominantly in AWS

    80% confidence
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,959
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,959 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
Amazon Q4 Earnings Miss Estimates, Shares Slide on $200B Capex Plan: Source | Via News | fr.via.news